+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myasthenia Gravis - Pipeline Review, H1 2019

  • ID: 4750103
  • Drug Pipelines
  • 152 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Bristol-Myers Squibb Co
  • Grifols SA
  • HanAll Biopharma Co Ltd
  • Novartis AG
  • Protalex Inc
  • MORE
Myasthenia Gravis - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H1 2019, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights

This latest pipeline guide Myasthenia Gravis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 5, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Bristol-Myers Squibb Co
  • Grifols SA
  • HanAll Biopharma Co Ltd
  • Novartis AG
  • Protalex Inc
  • MORE
Introduction

Myasthenia Gravis - Overview

Myasthenia Gravis - Therapeutics Development

Myasthenia Gravis - Therapeutics Assessment

Myasthenia Gravis - Companies Involved in Therapeutics Development

Myasthenia Gravis - Drug Profiles

Myasthenia Gravis - Dormant Projects

Myasthenia Gravis - Discontinued Products

Myasthenia Gravis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Myasthenia Gravis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H1 2019

Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H1 2019

Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H1 2019

Myasthenia Gravis - Pipeline by Argenx SE, H1 2019

Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H1 2019

Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H1 2019

Myasthenia Gravis - Pipeline by CuraVac Inc, H1 2019

Myasthenia Gravis - Pipeline by Grifols SA, H1 2019

Myasthenia Gravis - Pipeline by GT Biopharma Inc, H1 2019

Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H1 2019

Myasthenia Gravis - Pipeline by Momenta Pharmaceuticals Inc, H1 2019

Myasthenia Gravis - Pipeline by Neurotune AG, H1 2019

Myasthenia Gravis - Pipeline by Novartis AG, H1 2019

Myasthenia Gravis - Pipeline by Pfizer Inc, H1 2019

Myasthenia Gravis - Pipeline by Protalex Inc, H1 2019

Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H1 2019

Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2019

Myasthenia Gravis - Pipeline by Tolerion Inc, H1 2019

Myasthenia Gravis - Pipeline by UCB SA, H1 2019

Myasthenia Gravis - Dormant Projects, H1 2019

Myasthenia Gravis - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Myasthenia Gravis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Alpha Cancer Technologies Inc
  • Argenx SE
  • BioMarin Pharmaceutical Inc
  • Bristol-Myers Squibb Co
  • CuraVac Inc
  • Grifols SA
  • GT Biopharma Inc
  • HanAll Biopharma Co Ltd
  • Momenta Pharmaceuticals Inc
  • Neurotune AG
  • Novartis AG
  • Pfizer Inc
  • Protalex Inc
  • Ra Pharmaceuticals Inc
  • Toleranzia AB
  • Tolerion Inc
  • UCB SA
Note: Product cover images may vary from those shown
Adroll
adroll